PHARMACEUTICAL MARKET RESEARCH REPORTS
Industry Standard Research – ISR Reports – is a full-service pharmaceutical market research company operating exclusively in the life sciences industry and a sister company of BioProcess Online. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their pharmaceutical market syndicated research reports below.
ISR's market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available for to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.
TRENDS AND MARKET OUTLOOKS
Bioprocessing Market Trends and Outsourcing Dynamics: 2020-2025 (3rd Edition)
This market research report affords readers the opportunity to gain insight into the bioprocessing market and where it’s heading. This report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what our survey respondents predict the marketplace will look like in five years.
Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition)
This market research report goes into depth on the manufacturing aspect of biosimilars. Manufacturing these complex products in a cost efficient manner will be a critical component to successfully commercializing biosimilars and the anticipated boom.
Biologic Sterile Injectable Drug Product Manufacturing Market Overview and Outlook
This market research report provides an overview of the current biologic sterile injectable market dynamics as well as what our survey respondents—all outsourcing decision-makers—predict the market will look like in 2022. Key statistics include development-stage and marketed product volume, the proportion outsourced, and the number...
Pharmaceutical Excipient Market Overview and Outlook
This market research report offers readers the opportunity to gain insight into the biopharmaceutical excipient market and where it’s heading. Remaining aware of market dynamics and expected changes will enable readers to better make key decisions regarding excipient use and to help identify where competitive advantages may be gained.
Development vs Commercial Outsourced Manufacturing Practices: Biologics
This market research report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.
Central Lab Market Dynamics and Outsourcing Performance (2019-2022)
This report will help both study sponsors and providers answer a number of questions relevant to selecting and evaluating central lab service providers. For the purpose of this report, “central lab” is defined as a vendor that supplies specimen collection kits, logistics services, safety alerts, and a wide variety of laboratory testing services as well as providing lab reports to investigators.
QUALITY BENCHMARKING AND SERVICE PROVIDER PERFORMANCE
Bioanalytical Labs Market Dynamics and Service Provider Performance
Sponsors can use this report to evaluate their lab selection process. Bioanalytical labs can use it to learn how their company performs against competitors. Topics covered include lab selection and perceptions, lab performance, and lab service quality profiles.
Biologic Drug Product Contract Manufacturer Quality Benchmarking
This report gives an-depth look at a subset of respondents from small and emerging biopharma companies. It will help small and emerging biopharmaceutical companies make more informed CMO decisions, and will help CMOs optimize operational and marketing strategies.
DEPARTMENT MODELS AND STRUCTURES
The CMC Function: Best Practices and Optimization
ISR interviewed 15 CMC professionals at 14 Top 50 pharmaceutical and biotechnology companies, as well as one company outside the Top 50 to better understand the Chemistry Manufacturing and Controls function throughout the preclinical, clinical, and commercialization phases of the product development process.
Large Molecule vs Small Molecule Drug Product Outsourcing
In Q42020, ISR surveyed 110 sponsors who outsource biologic drug product manufacturing to gain insight into how drug product outsourcing is distributed at their organizations. 37% of respondents stated a larger proportion of biologic drug product manufacturing is outsourced compared to small molecule drug product. 39% said drug product manufacturing is outsourced at the same rate across molecule types.
CMOs Continue To Exceed Sponsor Expectations
ISR explains how the CMO Leadership Awards and the corresponding market research data can be used to make more informed CMO selection decisions and optimize operational and marketing strategies.
COVID-19's Impact On Outsourced Manufacturing
Over the past year, COVID-19 has impacted just about every aspect of our personal and professional lives. The pharmaceutical industry rose to myriad challenges brought on by the global pandemic. One of the high points has been the development, testing, and approval of multiple coronavirus vaccines in record time. The immediate and unpredicted need for billions of doses of a vaccine sent tidal waves through the biopharma industry, derailed strategic plans set in place years ago, and forced pharmaceutical companies to shift resources.
Warming Up To Hybrid Trials
Based on a Q4 2020 Industry Standard Research survey of clinical trials outsourcers, we offer insight on prevalence, respondents’ overall impressions, and the concerns and downsides of hybrid trials.
Reasons CDMOs Lose Oral Dose Manufacturing Bids
In Q2, 2019, ISR asked 101 respondents who outsource oral dose drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 30% of respondents’ votes.